MedMira
MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the...
top of page
MedMira
- Jun 6, 2022
- 4 min
MedMira Receives Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450)...
MedMira
- May 27, 2022
- 2 min
Update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe...
MedMira
- May 20, 2022
- 2 min
VYRA™ Product Line Update
Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for...
MedMira
- May 12, 2022
- 2 min
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its...
MedMira
- Mar 9, 2022
- 4 min
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and...
bottom of page